Mercier Nathalie, El Hadri Khadija, Osborne-Pellegrin Mary, Nehme Johnny, Perret Claudine, Labat Carlos, Regnault Veronique, Lamazière Jean-Marie Daniel, Challande Pascal, Lacolley Patrick, Fève Bruno
Inserm U684, Nancy, France.
Hypertension. 2007 Jul;50(1):234-41. doi: 10.1161/HYPERTENSIONAHA.107.089292. Epub 2007 Apr 23.
Semicarbazide-sensitive amine oxidase (SSAO)-deficient mice present no alteration in elastin cross-linking processes and carotid mechanical properties. In contrast, previous studies have shown that SSAO inhibitors induced marked anomalies in arterial structure and function. The aim of the present study was to examine the effect of semicarbazide (SCZ), an efficient SSAO inhibitor, on the arterial phenotype of the carotid artery in relation to modulation of SSAO and lysyl oxidase activities in growing rats. We first show that after 6 weeks of SCZ treatment (100 mg/kg per day), SSAO activity was reduced by 90%, whereas lysyl oxidase activity was only partially inhibited (<60%) in carotid artery, compared with controls. There was significant growth inhibition and no difference in mean arterial pressure but an increase in pulse pressure with a smaller arterial diameter in SCZ-treated rats. SCZ decreased aortic insoluble elastin without a change in total collagen. In addition, extracellular proteins other than insoluble elastin and collagen were increased in SCZ-treated rats. All of the elastic lamellae presented globular masses along their periphery, and focal disorganization was observed in the ascending aorta. Carotid artery mechanical strength was lower in SCZ-treated rats, and the elastic modulus-wall stress curve was shifted leftward compared with controls, indicating increased stiffness. Thus, SCZ modifies arterial geometry and mechanical properties, alters elastic fiber structure, and reduces the content of cross-linked elastin. Because these abnormalities are essentially absent in SSAO-deficient mice, our results suggest that lysyl oxidase inhibition is responsible for the major part of the vascular phenotype of SCZ-treated rats.
氨基脲敏感胺氧化酶(SSAO)缺陷型小鼠的弹性蛋白交联过程和颈动脉力学特性未发生改变。相比之下,先前的研究表明,SSAO抑制剂会导致动脉结构和功能出现明显异常。本研究的目的是探讨高效SSAO抑制剂氨基脲(SCZ)对生长中大鼠颈动脉动脉表型的影响,以及与SSAO和赖氨酰氧化酶活性调节的关系。我们首先发现,在SCZ治疗6周(每天100 mg/kg)后,与对照组相比,颈动脉中SSAO活性降低了90%,而赖氨酰氧化酶活性仅受到部分抑制(<60%)。SCZ治疗的大鼠出现显著的生长抑制,平均动脉压无差异,但脉压增加,动脉直径变小。SCZ降低了主动脉中不溶性弹性蛋白的含量,而总胶原蛋白含量没有变化。此外,SCZ治疗的大鼠中,除了不溶性弹性蛋白和胶原蛋白之外的细胞外蛋白质增加。所有弹性膜的周边均出现球状团块,升主动脉中观察到局灶性结构紊乱。SCZ治疗的大鼠颈动脉力学强度较低,与对照组相比,弹性模量-壁应力曲线向左移动,表明硬度增加。因此,SCZ改变了动脉几何形状和力学特性,改变了弹性纤维结构,并减少了交联弹性蛋白的含量。由于这些异常在SSAO缺陷型小鼠中基本不存在,我们的结果表明,赖氨酰氧化酶抑制是SCZ治疗大鼠血管表型的主要原因。